Activation of the type I interferon system in primary Sjögren's syndrome: A possible etiopathogenic mechanism

Arthritis and Rheumatism

Volumn 52, Issue 4, 2005, Pages 1185-1195

  Båve, Ullvi ^a   Nordmark, Gunnel ^a   Lövgren, Tanja ^a   Rönnelid, Johan ^a   Cajander, Stefan ^a   Eloranta, Maija Leena ^b   Alm, Gunnar V ^b   Rönnblom, Lars ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; FC RECEPTOR; INTERFERON; RNA BINDING PROTEIN;

APOPTOSIS; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; NECROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME;

APOPTOSIS; AUTOANTIBODIES; CARCINOMA, HEPATOCELLULAR; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERFERON INDUCERS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; MALE; NECROSIS; RNA-BINDING PROTEINS; SALIVARY GLANDS, MINOR; SJOGREN'S SYNDROME; U937 CELLS;

EID: 17244372491     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20998     Document Type: Article

References (45)

1. Tzioufas AG, Moutsopoulos HM. Sjögren's syndrome. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 3rd ed. Edinburgh: Mosby; 2003. p. 1431-43.
2. Hansen A, Lipsky PE, Dorner T. New concepts in the pathogenesis of Sjögren syndrome: many questions, fewer answers. Curr Opin Rheumatol 2003;15:563-70.
3. Manganelli P, Fietta P. Apoptosis and Sjögren syndrome. Semin Arthritis Rheum 2003;33:49-65.
4. James JA, Harley JB, Scofield RH. Role of viruses in systemic lupus erythematosus and Sjögren syndrome. Curr Opin Rheumatol 2001;13:370-6.
5. Levy DE, Marie I, Prakash A. Ringing the interferon alarm: differential regulation of gene expression at the interface between innate and adaptive immunity. Curr Opin Immunol 2003;15:52-8.
6. Bave U, Alm GV, Ronnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-α inducer. J Immunol 2000;165:3519-26.
7. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004;50:1861-72.
8. Stewart TA. Neutralizing interferon α as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev 2003;14:139-54.
9. Ronnblom L, Eloranta ML, Alm GV. Role of natural interferon-α producing cells (plasmacytoid dendritic cells) in autoimmunity. Autoimmunity 2003;36:463-72.
10. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991;115:178-83.
11. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000;43:1431-41.
12. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003;197:777-88.
13. Braun D, Geraldes P, Demengeot J. Type I interferon controls the onset and severity of autoimmune manifestations in 1pr mice. J Autoimmun 2003;20:15-25.
14. Fox RI, Robinson CA, Curd JG, Kozin F, Howell FV. Sjögren's syndrome: proposed criteria for classification. Arthritis Rheum 1986;29:577-85.
15. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
16. Daniels TE, Whitcher JP. Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca: analysis of 618 patients with suspected Sjögren's syndrome. Arthritis Rheum 1994;37:869-77.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
19. Vallin H, Perers A, Alm GV, Ronnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J Immunol 1999;163:6306-13.
20. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur J Immunol 2001;31:2154-63.
21. Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-α (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999;115:196-202.
22. Blomberg S, Eloranta ML, Magnusson M, Alm GV, Ronnblom L. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-α by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum 2003;48:2524-32.
23. Blomberg S, Eloranta ML, Cederblad B, Nordlind K, Alm GV, Ronnblom L. Presence of cutaneous interferon-α producing cells in patients with systemic lupus erythematosus. Lupus 2001;10:484-90.
24. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778-809.
25. Fitzgerald-Bocarsly P. Natural interferon-α producing cells: the plasmacytoid dendritic cells. Biotechniques 2002;33:S16-29.
26. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J Immunol 2003;171:3296-302.
27. Von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24:323-58.
28. Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J Exp Med 2001;194:1823-34.
29. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-31.
30. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004;303:1526-9.
31. Booth JW, Kim MK, Jankowski A, Schreiber AD, Grinstein S. Contrasting requirements for ubiquitylation during Fc receptor-mediated endocytosis and phagocytosis. EMBO J 2002;21:251-8.
32. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-7.
33. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7.
34. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003;19:837-47.
35. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-71.
36. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001;159:237-43.
37. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998;95:15623-8.
38. Kirou KA, Vakkalanka RK, Butler MJ, Crow MK. Induction of Fas ligand-mediated apoptosis by interferon-α. Clin Immunol 2000;95:218-26.
39. Salomonsson S, Jonsson MV, Skarstein K, Brokstad KA, Hjelmstrom P, Wahren-Herlenius M, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. Arthritis Rheum 2003;48:3187-201.
40. Ogawa N, Ping L, Zhenjun L, Takada Y, Sugai S. Involvement of the interferon-γ-induced T cell-attracting chemokines, interferon-γ- inducible 10-kd protein (CXCL10) and monokine induced by interferon-γ (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome. Arthritis Rheum 2002;46:2730-41.
41. Vanbervliet B, Bendriss-Vermare N, Massacrier C, Homey B, de Bouteiller O, Briere F, et al. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med 2003;198:823-30.
42. Hunziker L, Recher M, Macpherson AJ, Ciurea A, Freigang S, Hengartner H, et al. Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. Nat Immunol 2003;4:343-9.
43. Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-α for the treatment of xerostomia in patients with Sjögren's syndrome. J Interferon Cytokine Res 1998;18:255-62.
44. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjögren's syndrome with low-dose human interferon-α administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003;49:585-93.
45. Smith JK, Siddiqui AA, Modica LA, Dykes R, Simmons C, Schmidt J, et al. Interferon-α upregulates gene expression of aquaporin-5 in human parotid glands. J Interferon Cytokine Res 1999;19:929-35.